Microvascular basement membranes in diabetes mellitus

Journal of Pathology

Volumn 200, Issue 4, 2003, Pages 537-546

  Tsilibary, Effie C ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

Diabetes; Diabetic complications; Diabetic microangiopathy; Diabetic neuropathy; Diabetic retinopathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; COLLAGEN TYPE 4; GELATINASE A; INTEGRIN; OXYGEN RADICAL; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN;

CELL STRUCTURE; COLLAGEN SYNTHESIS; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; EPITHELIUM CELL; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HYPERGLYCEMIA; MICROVASCULARIZATION; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVIEW;

BASEMENT MEMBRANE; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; GLYCOSYLATION END PRODUCTS, ADVANCED; GROWTH SUBSTANCES; HUMANS; MATRIX METALLOPROTEINASES; MICROCIRCULATION;

EID: 0037899247     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1439     Document Type: Review

References (92)

1. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Diabetes 2001; 109(Suppl 2): S424-S437.
2. Caramoni ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49: 1399-1408.
3. Della Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab Suppl 2000; 4: 8-14.
4. Bjorn SF, Bangstad HJ, Hanssen KF, et al. Glomerular epithelial foot processes and filtration slits in IDDM patients. Diabetologia 1995; 38: 1197-1204.
5. Obineche EN, Mensah-Brown E, Chandranath SI, et al. Morphological changes in the rat kidney following long-term diabetes. Arch Physiol Biochem 2001; 109: 241-245.
6. White KE, Bilous RW, Marshall SM, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002; 51: 3083-3089.
7. Kitsiou P, Tzinia A, Stettler-Stevenson W, et al. Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 2003; 284: F671-F679.
8. Krishnamurti U, Yong C, Michael A, et al. Integrin-mediated interactions between primary/T-sv40 immortalized human glomerular epithelial cells and type IV collagen. Lab Invest 1996; 74: 650-657.
9. Regoli M, Bendayan M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia 1997; 40: 15-22.
10. Chen HC, Chen CA, Guh JY, et al. Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci 2000; 67: 2345-2353.
11. Yoon S, Gingras D, Bendayan M. Alterations of vitronectin and its receptor alpha(v) integrin in the rat renal glomerular wall during diabetes. Am J Kidney Dis 2001; 38: 1298-1306.
12. Chintala SK, Sawaya R, Gokaslan ZI, Rao JS. Modulation of matrix metalloprotease-2 and invasion in human glioma cells by alpha 3 beta 1 integrin. Cancer Lett 1996; 103: 201-208.t
13. Agrez M, Xinhua G, Turton J, et al. The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells. Int J Cancer 1999; 81: 90-97.
14. Sugiura T, Berditchevski F. Function of alpha3beta1-tetraspanin protein complexes in tumor cell invasion: evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP2). J Cell Biol 1999; 146: 1375-1389.
15. DiPersio M, Shao M, Di Costanzo, L, Kreidberg JA, Hynes RO. Mouse keratinocytes immortalized with large T antigen acquire alpha3beta1 integrin-dependent secretion of MMP-9/gelatinase B. J Cell Sci 2000; 113: 2909-2921.
16. Hofmann UB, Westphall JR, Van Kraats AA, Ruiter DJ, van Muijen GN. Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer 2000; 87: 12-19.
17. Wu K, Setty S, Mauer SM, et al. Altered kidney matrix gene expression in early stages of experimental diabetes. Acta Anat 1997; 158: 155-165.
18. Karamessinis P, Tzinia AK, Kitsiou PV, et al. Proximal tubular epithelial cell integrins respond to high glucose by altered cell-matrix interactions and differentially regulate matrixin expression. Lab Invest 2002; 82: 1081-1093.
19. Suzuki D, Yagame M, Kim Y, Sakai H, Mauer M. Renal in situ hybridization studies of extracellular matrix related molecules in type 1 diabetes mellitus. Nephron 2002; 92: 564-572.
20. Liu D, Razzaque MS, Cheng M, Taguchi T. The renal expression of heat shock protein 47 and collagens in acute and chronic experimental diabetes in rats. Histochem J 2001; 33: 621-628.
21. Cohen MP, Lautenslager GT, Shearman CW. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Metabolism 2001; 50: 1435-1540.
22. De Muro P, Fresu P, Formato M, et al. Urinary glycosaminoglycan and proteoglycan excretion in normoalbuminuric patients with type 1 diabetes mellitus. J Nephrol 2002; 15: 290-296.
23. Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57: 385-400.
24. Yard BA, Kahlert S, Engelleiter R, et al. Decreased glomerular expression of agrin in diabetic nephropathy and podocytes, cultured in high ilucose medium. Exp Nephrol 2001; 9: 214-222.
25. van der Pijl JW, Daha MR, van der Born J, et al. Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulphate in skin basement membrane. Diabetologia 1998; 41: 791-798.
26. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 4: 522-530.
27. Chen S, Carmen Iglesias-de la Cruz M, Jim B, et al. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003; 300: 16-22.
28. Cosgrove D, Rodgers K, Meehan D, et al. Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 2000; 157: 1649-1659.
29. Isono M, Chen S, Hong SW, Iglesias de la Cruz MC, Ziyade FN. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002; 296: 1356-1365.
30. Ng DP, Warram JH, Krolewski AS. TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. Am J Kidney Dis 2003; 41: 22-28.
31. Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JL. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991; 261: F571 -17577.
32. Ikehara K, Tada H, Kukobi K, Inokuchi T. Role of protein kinase C-angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels. Diabetes Res Clin Pract 2003; 59: 25-30.
33. Krishnamurti U, Michael AF, Rondeau E, et al. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem 1997; 272: 27 966-27 970.
34. Goruppi S, Bonventre JV, Kyriakis JM. Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 2002; 21: 5427-5436.
35. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in TGF-beta and fibronectin synthesis in mesangial cells. Diabetes 2002; 51: 3505-3509.
36. Reddy MA, Adler SG, Kim YS, et al. Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol 2002; 283: F985-F994.
37. Park CW, Kim JH, Lee JH, et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 2000; 43: 1544-1553.
38. Anderson SS, Wu K, Nagasi H, et al. Effect of matrix glycation on expression of type IV collagen, MMP-2, MMP-9 and TIMP-1 by human mesangial cells. Cell Adhes Commun 1996; 4: 89-101.
39. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25: 255-270.
40. Rong J, Qiu H, Wang S. Advanced glycosylation end products, protein kinase C and renal alterations in diabetic rats. Chin Med J (Engl) 2000; 113: 1087-1091.
41. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
42. Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1256-1266.
43. Azal O, Yonem A, Guler S, et al. Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats. Diabetes Obes Metab 2002; 4: 75-79.
44. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998; 47: 1114-1120.
45. Trevisan R, Viberti G. Sodium-hydrogen antiporter: its possible role in the genesis of diabetic nephropathy. Nephrol Dial Transplant 1997; 12: 643-645.
46. Monciotti CG, Semplicini A, Morocutti A, et al. Elevated sodium-lithium countertransport activity in erythrocytes is predictive of the development of microalbuminuria in IDDM. Diabetologia 1997; 40: 654-661.
47. Trevisan R, Fioreto P, Barbosa J, Mauer M. Insulin-dependent diabetic sibling pairs are concordant for sodium-hydrogen antiporter activity. Kidney Int 1999; 55: 2383-2389.
48. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-3094.
49. Nakagawa H, Sasahara M, Haneda M, et al. Diabetes immunohistochemical characterization of glomerular PDGF B-chain and PDGF beta-receptor expression in diabetic rats. Res Clin Pract 2000; 48: 87-98.
50. Cai W, Gao QD, Zhu L, et al. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8: 337-346.
51. Trachtman H, Futterweit S, Pine E, Mann J, Valderrana E. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatr Nephrol 2002; 17: 20-29.
52. Philips AO, Steadman R. Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury. Histol Histopathol 2002; 17: 247-252.
53. Morcos M, Sayed AA, Bierhaus A, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002; 51: 3532-3544.
54. Zeisberg M, Maeshima Y, Mosterman B, Kalluri R. Renal fibrosis: extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 2002; 160: 2001-2008.
55. Setty S, Anderson SS, Wayner EA, et al. Glucose-induced alteration of integrin expression and function in cultured human mesangial cells. Cell Adhes Commun 1995; 3: 187-200.
56. Dalla Vestra M, Saller A, Mauer M, Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol 2001; 4(Suppl): S51-57.
57. Couser WG, Johnson RJ. Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 1994; 23: 193-198.
58. Gambaro G, D'Angelo A, Del Prete D, et al. Mesangial cell proliferation in long-term streptozotocin-induced diabetes mellitus in the rat and the renoprotective activity of heparin. Am J Nephrol 1999; 19: 530-534.
59. Kugori Y. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 2003; 23: 15-31.
60. Homey MJ, Shirley KW, Kurtz DT, Rosenzweig SA. Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Am J Physiol 1998; 274: F1045-F1053.
61. Guo L, Wu C. Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex. FASEB J 2002; 16: 1298-3000.
62. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75.
63. Mott JD, Khalifah RG, Nagase H, et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997; 52: 1302-1312.
64. Henricsson M, Nystrom L, Blohme G, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003; 26: 349-354.
65. Chavers BM, Mauer SM, Ramsay RC, Steffes MW. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 1994; 43: 441-446.
66. Kim SH, Chu YK, Kwon OW, McCune SA, Davidorf FH. Morphologic studies of the retina in a new diabetic model: SHR/N: Mcc-cp rat. Yonsei Med J 1998; 39: 453-462.
67. Nishikawa T, Giardino I, Edelstein D, Brownlee M. Changes in diabetic retinal matrix protein mRNA levels in a common transgenic mouse strain. Curr Eye Res 2000; 21: 581-587.
68. Ito Y, Imamura S, Yamamoto K, et al. Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensinconverting enzyme inhibitor, analapril maleate. J Endocrinol 2002; 175: 233-239.
69. Spirin KS, Saghizadeh M, Lewin SL, et al. Basement membrane and growth factor gene expression in normal and diabetic human retinas. Curr Eye Res 1999; 18: 490-499.
70. Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 2000; 49: 662-666.
71. Ljubimov AV, Burgeson RE, Butkowksi RJ, et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem 1996; 44: 1469-1479.
72. Castellon R, Caballero S, Hamdi HK, et al. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci 2002; 43: 2758-2766.
73. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999; 40: 809-813.
74. Riecke B, Chavakis E, Bretzel RG, et al. Topical application of integrin antagonists inhibits proliferative retinopathy. Horm Metab Res 2001; 33: 307-311.
75. Chavakis E, Riecke B, Lin J, et al. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Diabetologia 2002; 45: 262-267.
76. Witmer AN, van den Born J, Vrensen GF, Schlingemann RO. Vascular localization of heparan sulfate proteoglycans in retinas of patients with diabetes mellitus and in VEGF-induced retinopathy using domain-specific antibodies. Curr Eye Res 2001; 22: 190-197.
77. Beltramo, E, Pomero F, Allione A, et al. Pericyte adhesion is impaired on extracellular matrix by endothelial cells in high hexose concentrations. Diabetologia 2002; 45: 416-419.
78. Kalfa TA, Gerritsen ME, Carlson EC, Binstock AJ, Tsilibary EC. Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalm Vis Sci 1995; 36: 2358-2367.
79. Hammes HP, Alt A, Niwa T, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999; 42: 728-736.
80. Xu X, Li Z, Luo D, et al. Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2003; 241: 56-62.
81. Hammes HP, Weiss A, Hess S, et al. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 1996; 75: 325 -338.
82. Clements RS, Robison WG, Cohen MP. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diabetes Complications 1998; 12: 28-33.
83. Amano S, Yarnagishi S, Kato N, et al. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem Biophys Res Commun 2002; 299: 183-188.
84. Park HK, Ahn CW, Lee GT, et al. (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 151-157.
85. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998; 47: 401-406.
86. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogen esis of diabetic retinopathy. Diabetes 2002; 51: 3107-3112.
87. Suzuma I, Suzuma K, Ueki K, et al. Stretch-induced retinal vascular endothelial factor expression is mediated by phosphatidylinositol 3-kinase and protein kinase C (PKC)-zeta but not by stretch-induced ERK1/2, Akt, Ras, or classical/novel PKC pathways. J Biol Chem 2002; 277: 1047-1057.
88. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998; 76: 21-31.
89. Mamputu JC, Renier G. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells: inhibitory effect of gliclazide. J Diabetes Complications 2002; 16: 284-293.
90. Vincent AM, Brownlee M, Russell JW. Oxidative stress and programmed cell death in diabetic neuropathy. Ann NY Acad Sci 2002; 959: 368-383.
91. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 2000; 77: S26-30.
92. Thomas S, Vanuystel J, Gruden G, et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 2000; 11: 1236-1243.